Fourth Hospital of Hebei Medical University
Welcome,         Profile    Billing    Logout  
 22 Trials 
25 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jiang, Zefei
NCT04514419: Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

Recruiting
3
408
RoW
HS627, Trastuzumab + HS627 + Docetaxel, Pertuzumab, Trastuzumab Pertuzumab Docetaxel
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd
Breast Cancer
11/21
11/21
TQB3616-III-01, NCT05375461: TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail

Active, not recruiting
3
287
RoW
TQB3616 capsules, TQB3616-matching placebo, Fluvestrin injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
HR-positive,HER2-negative in Advanced Breast Cancer
01/24
12/25
Dynasty-Breast01, NCT06265428: A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer

Recruiting
3
224
RoW
DB-1303/BNT323, T-DM1
DualityBio Inc., BioNTech SE
HER2-positive Breast Cancer
02/26
02/26
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
CAPItrue, NCT06635447: Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients

Recruiting
3
560
RoW
Capivasertib, AZD5363, Fulvestrant
AstraZeneca
Breast Cancer
10/26
10/26
MRG002-004, NCT04924699: A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting
2/3
350
RoW
MRG002, Trastuzumab Emtansine for Injection
Shanghai Miracogen Inc.
Advanced Breast Cancer, Metastatic Breast Cancer
09/23
10/23
NCT04159142: Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Recruiting
2
414
RoW
Nab-paclitaxel + Carboplatin, Nab-paclitaxel + Capecitabine
Hebei Medical University Fourth Hospital, Beijing 302 Hospital, CSPC Ouyi Pharmaceutical Co., Ltd.
Triple Negative Breast Cancer, Nab-paclitaxel
06/22
09/22
Magic-009, NCT05263869: A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

Recruiting
2
99
RoW
MRG002
Shanghai Miracogen Inc.
Breast Cancer With Liver Metastases
12/22
10/23
TQB3616-II-01, NCT04773418: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Recruiting
2
120
RoW
TQB3616 capsules, Fulvestrant injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
HR-positive, HER2-negative Advanced Breast Cancer
01/23
01/23
TQB3616-II-01, NCT04796623: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Recruiting
2
120
RoW
TQB3616 capsules, Fulvestrant injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
HR-positive, HER2-negative Advanced Breast Cancer
01/23
01/23
MRG002-005, NCT04742153: A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Recruiting
2
66
RoW
MRG002
Shanghai Miracogen Inc.
Advanced or Metastatic Breast Cancer
02/23
02/23
NCT05336721: A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Terminated
2
9
RoW
Chiauranib, capecitabine
Chipscreen Biosciences, Ltd.
Triple-negative Breast Cancer
10/24
11/24
NCT06167694: Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer

Recruiting
1/2
146
RoW
HRS-8080; Dalpiciclib Isethionate Tablets
Shandong Suncadia Medicine Co., Ltd.
Unresectable or Metastatic Breast Cancer
10/25
12/25
NCT05145179: A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors

Not yet recruiting
1
162
NA
SSGJ-705
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Receptor, ErbB-2
12/23
06/24
QLS12004-101, NCT05829616: A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors

Not yet recruiting
1
50
RoW
QLS12004
Qilu Pharmaceutical Co., Ltd.
Advanced Solid Tumor
05/24
05/25
Geng, cuizhi
NCT04790305: Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer

Recruiting
4
1072
RoW
Huaier Granule, Z20000109（NMPA Approval Number）
Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology
Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast
12/27
07/28
TQB2450-III-06, NCT04405505: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Not yet recruiting
3
332
RoW
TQB2450, Anlotinib, Paclitaxel for Injection (albumin bound)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Triple Negative Breast Cancer
07/22
07/22
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Recruiting
3
360
RoW
PM8002, Nab-Paclitaxel, Placebo
Biotheus Inc.
Triple Negative Breast Cancer(TNBC)
07/27
07/28
NCT05753865: A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)

Not yet recruiting
3
454
RoW
SYHX2011, Paclitaxel for injection (albumin-bound)
CSPC Ouyi Pharmaceutical Co., Ltd.
Advanced Breast Cancer
09/24
09/24
NCT05860465: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Recruiting
2/3
254
RoW
SPH4336 Tablets, SPH4336 Tablets Placebo
Shanghai Pharmaceuticals Holding Co., Ltd
Locally Advanced or Metastatic Breast Cancer
12/25
12/25
NCT04159142: Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Recruiting
2
414
RoW
Nab-paclitaxel + Carboplatin, Nab-paclitaxel + Capecitabine
Hebei Medical University Fourth Hospital, Beijing 302 Hospital, CSPC Ouyi Pharmaceutical Co., Ltd.
Triple Negative Breast Cancer, Nab-paclitaxel
06/22
09/22
MRG002-005, NCT04742153: A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Recruiting
2
66
RoW
MRG002
Shanghai Miracogen Inc.
Advanced or Metastatic Breast Cancer
02/23
02/23
NCT05872347: Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

Recruiting
2
52
RoW
SPH4336 Tablets
Shanghai Pharmaceuticals Holding Co., Ltd
Breast Cancer Brain Metastases
12/25
12/25
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Active, not recruiting
1/2
1410
Canada, US, RoW
SKB264, MK-2870, Sacituzumab Tirumotecan (Sac-TMT)
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Cervical Cancer
12/25
07/26
NCT05245058: SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

Recruiting
1
150
RoW
SPH5030 tablets
Shanghai Pharmaceuticals Holding Co., Ltd
HER2-positive Advanced Solid Tumors
12/25
12/25
Lihong, Liu
No trials found
Cuizhi, Geng
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jiang, Zefei
NCT04514419: Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

Recruiting
3
408
RoW
HS627, Trastuzumab + HS627 + Docetaxel, Pertuzumab, Trastuzumab Pertuzumab Docetaxel
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd
Breast Cancer
11/21
11/21
TQB3616-III-01, NCT05375461: TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail

Active, not recruiting
3
287
RoW
TQB3616 capsules, TQB3616-matching placebo, Fluvestrin injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
HR-positive,HER2-negative in Advanced Breast Cancer
01/24
12/25
Dynasty-Breast01, NCT06265428: A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer

Recruiting
3
224
RoW
DB-1303/BNT323, T-DM1
DualityBio Inc., BioNTech SE
HER2-positive Breast Cancer
02/26
02/26
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
CAPItrue, NCT06635447: Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients

Recruiting
3
560
RoW
Capivasertib, AZD5363, Fulvestrant
AstraZeneca
Breast Cancer
10/26
10/26
MRG002-004, NCT04924699: A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting
2/3
350
RoW
MRG002, Trastuzumab Emtansine for Injection
Shanghai Miracogen Inc.
Advanced Breast Cancer, Metastatic Breast Cancer
09/23
10/23
NCT04159142: Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Recruiting
2
414
RoW
Nab-paclitaxel + Carboplatin, Nab-paclitaxel + Capecitabine
Hebei Medical University Fourth Hospital, Beijing 302 Hospital, CSPC Ouyi Pharmaceutical Co., Ltd.
Triple Negative Breast Cancer, Nab-paclitaxel
06/22
09/22
Magic-009, NCT05263869: A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

Recruiting
2
99
RoW
MRG002
Shanghai Miracogen Inc.
Breast Cancer With Liver Metastases
12/22
10/23
TQB3616-II-01, NCT04773418: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Recruiting
2
120
RoW
TQB3616 capsules, Fulvestrant injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
HR-positive, HER2-negative Advanced Breast Cancer
01/23
01/23
TQB3616-II-01, NCT04796623: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Recruiting
2
120
RoW
TQB3616 capsules, Fulvestrant injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
HR-positive, HER2-negative Advanced Breast Cancer
01/23
01/23
MRG002-005, NCT04742153: A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Recruiting
2
66
RoW
MRG002
Shanghai Miracogen Inc.
Advanced or Metastatic Breast Cancer
02/23
02/23
NCT05336721: A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Terminated
2
9
RoW
Chiauranib, capecitabine
Chipscreen Biosciences, Ltd.
Triple-negative Breast Cancer
10/24
11/24
NCT06167694: Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer

Recruiting
1/2
146
RoW
HRS-8080; Dalpiciclib Isethionate Tablets
Shandong Suncadia Medicine Co., Ltd.
Unresectable or Metastatic Breast Cancer
10/25
12/25
NCT05145179: A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors

Not yet recruiting
1
162
NA
SSGJ-705
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Receptor, ErbB-2
12/23
06/24
QLS12004-101, NCT05829616: A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors

Not yet recruiting
1
50
RoW
QLS12004
Qilu Pharmaceutical Co., Ltd.
Advanced Solid Tumor
05/24
05/25
Geng, cuizhi
NCT04790305: Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer

Recruiting
4
1072
RoW
Huaier Granule, Z20000109（NMPA Approval Number）
Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology
Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast
12/27
07/28
TQB2450-III-06, NCT04405505: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Not yet recruiting
3
332
RoW
TQB2450, Anlotinib, Paclitaxel for Injection (albumin bound)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Triple Negative Breast Cancer
07/22
07/22
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Recruiting
3
360
RoW
PM8002, Nab-Paclitaxel, Placebo
Biotheus Inc.
Triple Negative Breast Cancer(TNBC)
07/27
07/28
NCT05753865: A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)

Not yet recruiting
3
454
RoW
SYHX2011, Paclitaxel for injection (albumin-bound)
CSPC Ouyi Pharmaceutical Co., Ltd.
Advanced Breast Cancer
09/24
09/24
NCT05860465: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Recruiting
2/3
254
RoW
SPH4336 Tablets, SPH4336 Tablets Placebo
Shanghai Pharmaceuticals Holding Co., Ltd
Locally Advanced or Metastatic Breast Cancer
12/25
12/25
NCT04159142: Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Recruiting
2
414
RoW
Nab-paclitaxel + Carboplatin, Nab-paclitaxel + Capecitabine
Hebei Medical University Fourth Hospital, Beijing 302 Hospital, CSPC Ouyi Pharmaceutical Co., Ltd.
Triple Negative Breast Cancer, Nab-paclitaxel
06/22
09/22
MRG002-005, NCT04742153: A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Recruiting
2
66
RoW
MRG002
Shanghai Miracogen Inc.
Advanced or Metastatic Breast Cancer
02/23
02/23
NCT05872347: Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

Recruiting
2
52
RoW
SPH4336 Tablets
Shanghai Pharmaceuticals Holding Co., Ltd
Breast Cancer Brain Metastases
12/25
12/25
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Active, not recruiting
1/2
1410
Canada, US, RoW
SKB264, MK-2870, Sacituzumab Tirumotecan (Sac-TMT)
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Cervical Cancer
12/25
07/26
NCT05245058: SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

Recruiting
1
150
RoW
SPH5030 tablets
Shanghai Pharmaceuticals Holding Co., Ltd
HER2-positive Advanced Solid Tumors
12/25
12/25
Lihong, Liu
No trials found
Cuizhi, Geng
No trials found

Download Options